Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Stock Rating Upgraded by Barclays

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was upgraded by equities researchers at Barclays to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Swedish Orphan Biovitrum AB (publ) Price Performance

Swedish Orphan Biovitrum AB (publ) stock opened at $28.30 on Wednesday. The firm has a market capitalization of $10.07 billion, a P/E ratio of 47.97 and a beta of 0.51. The stock’s fifty day simple moving average is $28.81 and its 200-day simple moving average is $28.35. Swedish Orphan Biovitrum AB has a twelve month low of $22.87 and a twelve month high of $32.25. The company has a current ratio of 0.73, a quick ratio of 0.49 and a debt-to-equity ratio of 0.30.

Swedish Orphan Biovitrum AB (publ) Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.